Natural history of bivalvular functional regurgitation.
Aged
Atrial Natriuretic Factor
/ blood
Austria
Biomarkers
/ blood
Cause of Death
Echocardiography
Electrocardiography
Female
Heart Failure
/ diagnostic imaging
Humans
Male
Middle Aged
Mitral Valve Insufficiency
/ complications
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Registries
Stroke Volume
Tricuspid Valve Insufficiency
/ complications
bivalvular
functional mitral regurgitation
functional tricuspid regurgitation
heart failure
heart failure with reduced ejection fraction
mitral regurgitation
mitral valve
multiple valve disease
secondary mitral regurgitation
secondary tricuspid regurgitation
tricuspid regurgitation
tricuspid valve
Journal
European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
received:
22
08
2018
accepted:
29
10
2018
pubmed:
7
12
2018
medline:
11
8
2020
entrez:
4
12
2018
Statut:
ppublish
Résumé
Bivalvular functional regurgitation (BVFR) defined as concomitant mitral and tricuspid insufficiency has not been described or systematically assessed before. Therefore, this study sought to define incidence, impact and natural history of BVFR in heart failure with reduced ejection fraction (HFrEF) to provide the foundation for risk assessment and directions for potential treatment strategies. We enrolled 1021 consecutive patients with HFrEF under guideline-directed medical therapy and performed comprehensive echocardiographic and neurohumoral profiling. All-cause mortality during a 5 years of follow-up served as the primary endpoint. Thirty percent of patients suffered from moderate or severe BVFR. Long-term mortality increased with the presence and severity of functional regurgitation (FR) with severe BVFR representing the highest risk-subset (P < 0.001). Severe BVFR patients were more symptomatic and displayed an adverse remodelling and neurohumoral activation pattern (all P < 0.05). Severe BVFR was associated with excess mortality independently of clinical [adjusted hazard ratio (HR) 1.52, 95% confidence interval (CI) 1.39-1.84; P < 0.001] and echocardiographic (adjusted HR 1.31, 95% CI 1.11-1.54; P = 0.001) confounders, guideline-directed medical therapy (adjusted HR 1.55, 95% CI 1.35-1.79; P < 0.001) and neurohumoral activation (adjusted HR 1.31, 95% CI 1.07-1.59; P = 0.009). Moderate BVFR (n = 99) comprised equal baseline characteristics and similar risk as isolated severe FR (HR 0.95, 95% CI 0.69-1.30; P = 0.73). This long-term outcome study shows the multi-faceted nature of FR and defines BVFR as an important clinical entity associated with impaired functional class, adverse cardiac remodelling, and excess risk of mortality. Moderate BVFR conveys similar risk as isolated severe FR reflecting the deleterious impact of the global regurgitant load on the failing heart and the need of an integrated understanding for risk-assessment.
Identifiants
pubmed: 30508183
pii: 5224510
doi: 10.1093/ehjci/jey178
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
midregional pro-atrial natriuretic peptide, human
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Atrial Natriuretic Factor
85637-73-6
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-573Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.